Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Zenas Biopharma (ZBIO)
-
-
-
-
-
-
-
Zenas BioPharma, Inc. (ZBIO) Reports Q3 Loss of $1.22
-
-
-
-
-
-
-
Citi Reiterates Buy Rating on Zenas Biopharma (ZBIO)
-
-
-
-
-
-
-
Faruqi & Faruqi Reminds Zenas BioPharma Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 16, 2025 - ZBIO
-
-
-
-
-
-
-
ZBIO IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the F
-
-
-
-
-
-
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ZBIO
-
-
-
-
-
-
-
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
-
443,847 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

